BioSpace News Archive

Medicus IT, a trailblazer in healthcare technology solutions, proudly announces the appointment of Emily Sorrick as Chief People Officer.

Sequel, a startup, dedicated to engineering better health and wellness experiences for women, today announced that its breakthrough spiral tampon has received approval from the United States Food and Drug Administration (FDA) as a medical device.

Telesair, Inc., an innovator of next-generation respiratory care, and JPP Care, a leading Thai distributor of respiratory devices, jointly announced today that Telesair’s Bonhawa High Flow Oxygen Therapy (HFOT) system has been approved by Thailand’s Food and Drug Administration (Thai FDA) for use in the treatment of patients with respiratory insufficiency.

Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for TIBSOVO® (ivosidenib tablets) in the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS).

In a development that could accelerate the discovery of new diagnostics and treatments, researchers at Children’s Hospital of Philadelphia have developed a versatile and low-cost technology for targeted sequencing of full-length RNA molecules.

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier -crossing platform technology to address challenging disease areas with high unmet need.

Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT) today announced the closing of the sale of an additional 714,272 shares of Series A common stock at the initial public offering price of $16.00 per share pursuant to the partial exercise of the underwriters’ option to purchase additional shares, in connection with its initial public offering that closed on July 18, 2023.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx® in venous leg ulcers.

The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Joan Levy, PhD and MRA Chief Executive Officer Marc Hurlbert, PhD on the Food & Drug Administration approval of Hepzato Kit for patients with uveal melanoma with liver metastases that cannot be surgically removed.

YS Biopharma Co., Ltd. announced its unaudited financial results for the first quarter of the fiscal year ended March 31, 2024.